JP2018052902A - Aqueous solid ointment - Google Patents
Aqueous solid ointment Download PDFInfo
- Publication number
- JP2018052902A JP2018052902A JP2016194454A JP2016194454A JP2018052902A JP 2018052902 A JP2018052902 A JP 2018052902A JP 2016194454 A JP2016194454 A JP 2016194454A JP 2016194454 A JP2016194454 A JP 2016194454A JP 2018052902 A JP2018052902 A JP 2018052902A
- Authority
- JP
- Japan
- Prior art keywords
- fatty acid
- solid ointment
- aqueous solid
- crystal precipitation
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 75
- 239000007787 solid Substances 0.000 title claims abstract description 75
- -1 fatty acid salt Chemical class 0.000 claims abstract description 62
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 60
- 239000000194 fatty acid Substances 0.000 claims abstract description 60
- 229930195729 fatty acid Natural products 0.000 claims abstract description 60
- 229930006000 Sucrose Natural products 0.000 claims abstract description 27
- 239000005720 sucrose Substances 0.000 claims abstract description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 230000000202 analgesic effect Effects 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 5
- 229960002390 flurbiprofen Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229960001259 diclofenac Drugs 0.000 claims description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 239000013078 crystal Substances 0.000 abstract description 40
- 238000001556 precipitation Methods 0.000 abstract description 40
- 230000007774 longterm Effects 0.000 abstract description 11
- 238000002156 mixing Methods 0.000 abstract description 10
- 230000006866 deterioration Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 7
- 230000008025 crystallization Effects 0.000 description 7
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 6
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 235000021314 Palmitic acid Nutrition 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 239000005639 Lauric acid Substances 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000021357 Behenic acid Nutrition 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 229940116226 behenic acid Drugs 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- BAVONGHXFVOKBV-UHFFFAOYSA-N Carveol Chemical compound CC(=C)C1CC=C(C)C(O)C1 BAVONGHXFVOKBV-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 2
- 229960003338 crotamiton Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- BAVONGHXFVOKBV-ZJUUUORDSA-N (-)-trans-carveol Natural products CC(=C)[C@@H]1CC=C(C)[C@@H](O)C1 BAVONGHXFVOKBV-ZJUUUORDSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- YSTPAHQEHQSRJD-UHFFFAOYSA-N 3-Carvomenthenone Chemical compound CC(C)C1CCC(C)=CC1=O YSTPAHQEHQSRJD-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical group CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- YTAOBBFIOAEMLL-REQDGWNSSA-N Luliconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@H](CS\1)SC/1=C(\C#N)N1C=NC=C1 YTAOBBFIOAEMLL-REQDGWNSSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- RDIVANOKKPKCTO-UHFFFAOYSA-K aluminum;octadecanoate;hydroxide Chemical compound [OH-].[Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O RDIVANOKKPKCTO-UHFFFAOYSA-K 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229930007646 carveol Natural products 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- QAKXLTNAJLFSQC-UHFFFAOYSA-N hexadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC QAKXLTNAJLFSQC-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N isomenthone Natural products CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical group CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 229960000570 luliconazole Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical group [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229930006968 piperitone Natural products 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 229940032159 propylene carbonate Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229930006978 terpinene Natural products 0.000 description 1
- 150000003507 terpinene derivatives Chemical class 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- RBNWAMSGVWEHFP-UHFFFAOYSA-N trans-p-Menthane-1,8-diol Chemical compound CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1
Abstract
Description
本発明は、脂肪酸塩の結晶析出を抑制することができ、長期間の保存安定性および低温での保存安定性に優れた水性固形軟膏に関する。さらに詳しくは、本発明は、水性固形軟膏中にショ糖脂肪酸エステルを配合することで、脂肪酸塩の結晶析出を抑制することができ、長期間の保存安定性および低温での保存安定性に優れた水性固形軟膏に関するものである。 The present invention relates to an aqueous solid ointment that can suppress crystallization of fatty acid salts and is excellent in long-term storage stability and storage stability at low temperatures. More specifically, the present invention can suppress crystallization of fatty acid salts by blending a sucrose fatty acid ester in an aqueous solid ointment, and has excellent long-term storage stability and storage stability at low temperatures. The present invention relates to an aqueous solid ointment.
固形軟膏は、押し出し式やダイヤル繰り出し式密封容器など適当な容器に充填して用いることで、使用時に手指を汚すことなく患部に塗布することができること、範囲を限定して投与することができること、携帯に便利であることなど多くの利点があり、これまでにさまざまな商品が提案され、上市されている。 The solid ointment can be applied to the affected area without contaminating the fingers during use by filling an appropriate container such as an extrusion type or dial-feed type sealed container, and can be administered in a limited range. There are many advantages such as being convenient to carry, and various products have been proposed and marketed so far.
固形軟膏は、その原料の違いにより、主に、油性固形軟膏および水性固形軟膏に分類することができる。
油性固形軟膏は、流動パラフィンなどの油性液体成分およびミツロウやパラフィンワックスなどの油性凝固成分を主成分として製造されるため、皮膚に塗布した際にべたつきが生じ、使用感が著しく悪い課題がある。
Solid ointments can be classified mainly into oily solid ointments and aqueous solid ointments, depending on the difference in their raw materials.
Oily solid ointments are produced with oily liquid components such as liquid paraffin and oily coagulation components such as beeswax and paraffin wax as the main components.
一方、水性固形軟膏は、低級アルコールなどの揮発性液体成分と脂肪酸塩などの凝固成分を用いて製造される。揮発性成分を配合するため、油性固形軟膏と比較して、皮膚に塗布したの際のべたつきを抑えることができ、また、高い清涼感も得られるため、使用感が極めて良好である。しかしながら、水性固形軟膏は、保存安定性が悪く、長期間の保存や低温での保存により、容易に脂肪酸塩の結晶が析出し、外観の悪化、有効性や安全性に変化が生じる課題があった。 On the other hand, the aqueous solid ointment is produced using a volatile liquid component such as a lower alcohol and a coagulating component such as a fatty acid salt. Since a volatile component is blended, stickiness when applied to the skin can be suppressed as compared with oily solid ointment, and since a high refreshing feeling can be obtained, the feeling of use is very good. However, aqueous solid ointments have poor storage stability, and there is a problem that fatty acid salt crystals easily precipitate due to long-term storage or storage at low temperatures, resulting in deterioration in appearance and changes in effectiveness and safety. It was.
脂肪酸塩の結晶析出を抑制する技術としては、これまでに、特許文献１では多量の多価アルコールを配合する技術、特許文献２では高分子成分と分岐鎖高級脂肪酸を配合する技術、特許文献３ではアルミニウム塩を配合する技術、特許文献４ではイソプロパノールを配合する技術などが開発されている。しかし、いずれの技術も、脂肪酸塩の結晶析出を十分に抑制できるものでは無かった。 As a technique for suppressing the precipitation of fatty acid salt crystals, Patent Document 1 discloses a technique for blending a large amount of polyhydric alcohol, Patent Document 2 discloses a technique for blending a polymer component and a branched higher fatty acid, Patent Document 3 Has developed a technique of blending an aluminum salt, and Patent Document 4 has developed a technique of blending isopropanol. However, none of the techniques can sufficiently suppress the precipitation of fatty acid salts.
したがって、脂肪酸塩の結晶析出を抑制することができ、長期間の保存安定性および低温での保存安定性に優れた水性固形軟膏の開発が望まれていた。 Accordingly, it has been desired to develop an aqueous solid ointment that can suppress the precipitation of fatty acid salt crystals and is excellent in long-term storage stability and storage stability at low temperatures.
本発明の目的は、上記の状況を鑑みてなされたもので、脂肪酸塩の結晶析出を抑制することができ、長期間の保存安定性および低温での保存安定性に優れた水性固形軟膏を提供することである。 The object of the present invention was made in view of the above situation, and provides an aqueous solid ointment that can suppress crystallization of fatty acid salts and has excellent long-term storage stability and low-temperature storage stability. It is to be.
本発明者らは、前記課題を解決するべく鋭意検討した結果、水性固形軟膏中にショ糖脂肪酸エステルを配合することで、脂肪酸塩の結晶析出を抑制することができ、長期間の保存安定性および低温での保存安定性に優れた水性固形軟膏が得られることを見出し、この知見に基づき、本発明を完成するに至った。
すなわち、本発明は、以下の（１）〜（５）に示したものである。
（１）ショ糖脂肪酸エステル、脂肪酸塩、低級アルコールおよび有効成分を含むことを特徴とする水性固形軟膏。
（２）ショ糖脂肪酸エステルが、組成中に脂肪酸のモノエステル化体を含むことを特徴とする（１）に記載の水性固形軟膏。
（３）ショ糖脂肪酸エステルの配合量が０．００１〜１０重量％、脂肪酸塩の配合量が１〜２０重量％、低級アルコールの配合量が２０〜９０重量％および有効成分の配合量が０．１〜３０重量％であることを特徴とする（１）または（２）に記載の水性固形軟膏。
（４）有効成分が、消炎鎮痛成分であることを特徴とする（１）〜（３）のいずれかに記載の水性固形軟膏。
（５）消炎鎮痛成分が、ジクロフェナク、フルルビプロフェンまたはこれらの塩であることを特徴とする（１）〜（４）のいずれかに記載の水性固形軟膏。
As a result of intensive studies to solve the above problems, the present inventors can suppress crystallization of fatty acid salts by blending a sucrose fatty acid ester into an aqueous solid ointment, and can provide long-term storage stability. In addition, the present inventors have found that an aqueous solid ointment excellent in storage stability at low temperatures can be obtained, and based on this finding, the present invention has been completed.
That is, this invention is shown to the following (1)-(5).
(1) An aqueous solid ointment comprising a sucrose fatty acid ester, a fatty acid salt, a lower alcohol and an active ingredient.
(2) The aqueous solid ointment according to (1), wherein the sucrose fatty acid ester contains a monoesterified product of fatty acid in the composition.
(3) The amount of sucrose fatty acid ester is 0.001 to 10% by weight, the amount of fatty acid salt is 1 to 20% by weight, the amount of lower alcohol is 20 to 90% by weight, and the amount of active ingredients is 0 The aqueous solid ointment according to (1) or (2), characterized by being from 1 to 30% by weight.
(4) The aqueous solid ointment according to any one of (1) to (3), wherein the active ingredient is an anti-inflammatory analgesic ingredient.
(5) The aqueous solid ointment according to any one of (1) to (4), wherein the anti-inflammatory analgesic component is diclofenac, flurbiprofen or a salt thereof.
以上述べたように、本発明は、脂肪酸塩の結晶析出を抑制することができ、長期間の保存安定性および低温での保存安定性に優れた水性固形軟膏を提供することができる。 As described above, the present invention can provide an aqueous solid ointment that can suppress crystallization of fatty acid salts and is excellent in long-term storage stability and storage stability at low temperatures.
以下、本発明の水性固形軟膏を詳細に説明する。なお、本明細書に記載の例示は、本発明を特に限定するものではない。
本発明の「保存安定性」とは、水性固形軟膏を４℃で３箇月間、または２５℃で６箇月間保存した際の水性固形軟膏中の脂肪酸塩の結晶析出の状態を意味し、両保存条件にて結晶の析出を認めない場合を「保存安定性が良好である」と判断し、いずれかの保存条件にて結晶の析出を認めた場合を「保存安定性が不良である」と判断した。
Hereinafter, the aqueous solid ointment of the present invention will be described in detail. Note that the examples described in the present specification do not particularly limit the present invention.
The “storage stability” of the present invention means the state of crystal precipitation of fatty acid salt in the aqueous solid ointment when the aqueous solid ointment is stored at 4 ° C. for 3 months or at 25 ° C. for 6 months. The case where no crystal precipitation was observed under storage conditions was judged as “good storage stability”, and the case where crystal precipitation was observed under any storage conditions was “poor storage stability”. It was judged.
本発明に用いる有効成分としては、経皮吸収させることが可能であり、医学的または薬学的に許容できるものであれば、特に限定はないが、例えば、リドカイン、プロカイン、テトラカイン、アミノ安息香酸エチルなどの局所麻酔成分、ジフェンヒドラミン、マレイン酸クロルフェニラミンなどの抗ヒスタミン成分、ケトコナゾール、フルコナゾール、ラノコナゾール、ルリコナゾールなどの抗真菌成分、ロキソプロフェン、インドメタシン、ジクロフェナク、フルルビプロフェンおよびこれらの塩などの消炎鎮痛成分などが挙げられ、単独または２種以上組み合わせて用いることができるが、好ましくは消炎鎮痛成分であり、より好ましくはジクロフェナク、フルルビプロフェンおよびこれらの塩である。
有効成分の配合量としては、本発明の効果を損なわない範囲であれば特に限定はないが、０．１〜３０重量％であることが好ましく、より好ましくは０．５〜１０重量％である。有効成分の性質、投与量、経皮吸収性、有効血中濃度などを勘案し、適宜、調整して配合することができる。
The active ingredient used in the present invention is not particularly limited as long as it can be absorbed percutaneously and is medically or pharmaceutically acceptable. For example, lidocaine, procaine, tetracaine, aminobenzoic acid Anti-inflammatory agents such as local anesthetic components such as ethyl, antihistamine components such as diphenhydramine and chlorpheniramine maleate, antifungal components such as ketoconazole, fluconazole, lanconazole and luliconazole, loxoprofen, indomethacin, diclofenac, flurbiprofen and their salts An analgesic component and the like can be mentioned, and these can be used alone or in combination of two or more, but are preferably anti-inflammatory analgesic components, more preferably diclofenac, flurbiprofen and salts thereof.
The amount of the active ingredient is not particularly limited as long as it does not impair the effects of the present invention, but is preferably 0.1 to 30% by weight, more preferably 0.5 to 10% by weight. . In consideration of the nature of the active ingredient, the dose, transdermal absorbability, effective blood concentration, etc., it can be appropriately adjusted and blended.
本発明に用いるショ糖脂肪酸エステルとしては、医学的または薬学的に許容できるものであれば、特に限定はない。
ショ糖に結合する脂肪酸としては、例えば、カプリル酸、カプリン酸、ラウリン酸、ステアリン酸、パルミチン酸、ミリスチン酸、オレイン酸、ラウリン酸、アラキジン酸、ベヘニン酸、エルカ酸、リノール酸、リノレン酸などが挙げられ、単独または２種以上をエステル結合させて用いることができるが、好ましくはラウリン酸、ステアリン酸、パルミチン酸、ミリスチン酸、オレイン酸であり、より好ましくはステアリン酸、パルミチン酸、ミリスチン酸、オレイン酸である。
ショ糖脂肪酸エステルのエステル化比率としては、モノエステル体を含むものが好ましく、より好ましくはモノエステル化比率が４０％以上、さらに好ましくはモノエステル比率が５０％以上である。また、結合脂肪酸の種類かつまたはエステル化比率が異なるものを２種類以上混合して用いることもできる。
ショ糖脂肪酸エステルの配合量は、０．００１〜１０重量％であることが好ましく、より好ましくは０．００５〜５重量％、さらに好ましくは０．０１〜３重量％である。０．００１重量％未満では、十分に脂肪酸塩の結晶析出を抑制することができず、１０重量％超では、水性固形軟膏中に一部不溶となり、外観が悪くなることから好ましくない。
The sucrose fatty acid ester used in the present invention is not particularly limited as long as it is medically or pharmaceutically acceptable.
Examples of fatty acids that bind to sucrose include caprylic acid, capric acid, lauric acid, stearic acid, palmitic acid, myristic acid, oleic acid, lauric acid, arachidic acid, behenic acid, erucic acid, linoleic acid, and linolenic acid. These may be used alone or in combination of two or more, but are preferably lauric acid, stearic acid, palmitic acid, myristic acid, oleic acid, more preferably stearic acid, palmitic acid, myristic acid. Oleic acid.
The esterification ratio of the sucrose fatty acid ester is preferably one containing a monoester, more preferably the monoesterification ratio is 40% or more, and further preferably the monoester ratio is 50% or more. In addition, two or more types of bonded fatty acids with different esterification ratios may be used.
It is preferable that the compounding quantity of sucrose fatty acid ester is 0.001 to 10 weight%, More preferably, it is 0.005 to 5 weight%, More preferably, it is 0.01 to 3 weight%. If it is less than 0.001% by weight, crystallization of the fatty acid salt cannot be sufficiently suppressed, and if it exceeds 10% by weight, it is partially insoluble in the aqueous solid ointment and the appearance is deteriorated.
本発明に用いる脂肪酸塩としては、例えば、カプリン酸、カプリル酸、ラウリン酸、ミリスチン酸、パルミチン酸、ステアリン酸、アラキジン酸、ベヘニン酸、オレイン酸、イソステアリン酸、リノール酸、リノレン酸などの炭素数６〜２２の飽和または不飽和脂肪酸の塩が挙げられ、単独または２種以上組み合わせて用いることができるが、好ましくは、ミリスチン酸、パルミチン酸、ステアリン酸、アラキジン酸、ベヘニン酸、オレイン酸、イソステアリン酸のナトリウム塩またはカリウム塩である。また、ケン化などにより、水性固形軟膏の調製工程中に、脂肪酸塩を反応生成させることもできる。
これらの脂肪酸塩の配合量は、１〜２０重量％であることが好ましく、より好ましくは２〜１５重量％、さらに好ましくは３〜１０重量％である。
Examples of fatty acid salts used in the present invention include, for example, capric acid, caprylic acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, oleic acid, isostearic acid, linoleic acid, and linolenic acid. Examples thereof include salts of 6 to 22 saturated or unsaturated fatty acids, which can be used alone or in combination of two or more. Preferably, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, oleic acid, isostearic acid are used. The sodium or potassium salt of the acid. Moreover, a fatty acid salt can also be produced by reaction during the preparation process of the aqueous solid ointment by saponification or the like.
The blending amount of these fatty acid salts is preferably 1 to 20% by weight, more preferably 2 to 15% by weight, and still more preferably 3 to 10% by weight.
本発明に用いる低級アルコールとしては、例えば、メタノール、エタノール、プロパノール、イソプロパノール、ブタノール、ペンタノール、ヘキサノールなどの炭素数６以下の低級アルコールおよびこれらの変性物などを挙げることができ、単独または２種以上組み合わせて用いることができるが、好ましくはメタノール、エタノール、プロパノール、イソプロパノール、ブタノールなどの炭素数１〜４の低級アルコールおよびこれらの変性物であり、より好ましくはメタノール、エタノール、イソプロパノール、ゲラニオール変性エタノール、メタノール変性エタノール、八アセチルショ糖変性エタノールである。低級アルコールの配合量は、２０〜９０重量％であることが好ましく、より好ましくは３０〜８５重量％、さらに好ましくは４０〜７５重量％である。 Examples of the lower alcohol used in the present invention include lower alcohols having 6 or less carbon atoms such as methanol, ethanol, propanol, isopropanol, butanol, pentanol, and hexanol, and modified products thereof. These can be used in combination, but are preferably lower alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propanol, isopropanol, butanol and modified products thereof, more preferably methanol, ethanol, isopropanol, geraniol-modified ethanol. Methanol-modified ethanol and octaacetylsucrose-modified ethanol. The blending amount of the lower alcohol is preferably 20 to 90% by weight, more preferably 30 to 85% by weight, and still more preferably 40 to 75% by weight.
本発明の水性固形軟膏は、上記必須成分のほか、本発明の効果を損なわない範囲で医薬品を調製するにあたって許容される各種成分、すなわち、多価アルコール成分、ｐＨ調整成分、水、高級アルコール成分、界面活性成分、薬物溶解成分、精油成分、保湿成分、酸化防止成分、薬物安定化成分などを適宜配合することができる。 In addition to the above essential components, the aqueous solid ointment of the present invention is allowed to prepare various components that do not impair the effects of the present invention, that is, polyhydric alcohol component, pH adjusting component, water, higher alcohol component A surfactant component, a drug-dissolving component, an essential oil component, a moisturizing component, an antioxidant component, a drug stabilizing component, and the like can be appropriately blended.
多価アルコール成分としては、例えば、エチレングリコール、ジエチレングリコール、ポリエチレングリコール、１，３−ブチレングリコール、プロピレングリコール、ジプロピレングリコールなどが挙げられ、単独または２種以上組み合わせて用いることができる。 Examples of the polyhydric alcohol component include ethylene glycol, diethylene glycol, polyethylene glycol, 1,3-butylene glycol, propylene glycol, dipropylene glycol and the like, and these can be used alone or in combination of two or more.
ｐＨ調整成分としては、例えば、塩酸、酢酸、酢酸ナトリウム、酒石酸、酒石酸ナトリウム、水酸化ナトリウム、炭酸ナトリウム、炭酸水素ナトリウム、乳酸、乳酸ナトリウム、リンゴ酸、リンゴ酸ナトリウムなどが挙げられ、単独または２種以上組み合わせて用いることができる。 Examples of the pH adjusting component include hydrochloric acid, acetic acid, sodium acetate, tartaric acid, sodium tartrate, sodium hydroxide, sodium carbonate, sodium bicarbonate, lactic acid, sodium lactate, malic acid, sodium malate, and the like. It can be used in combination of more than one species.
水としては、例えば、精製水、滅菌水、天然水、常水、注射用水などが挙げられ、単独または２種以上組み合わせて用いることができる。 Examples of water include purified water, sterilized water, natural water, normal water, and water for injection, and can be used alone or in combination of two or more.
高級アルコール成分としては、例えば、オレイルアルコール、ステアリルアルコール、セタノール、ミリスチルアルコール、ラウリルアルコールなどが挙げられ、単独または２種以上組み合わせて用いることができる。 Examples of the higher alcohol component include oleyl alcohol, stearyl alcohol, cetanol, myristyl alcohol, lauryl alcohol, and the like, and these can be used alone or in combination of two or more.
界面活性成分としては、例えば、アルキルアリルポリエーテルアルコール、高級アルコール硫酸化物、自己乳化型モノステアリン酸グリセリン、ソルビタン脂肪酸エステル、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンポリオキシプロピレングリコール、プロピレングリコール脂肪酸エステル、ポリグリセリン脂肪酸エステル、モノグリセリン脂肪酸エステル、ラウロマクロゴール、ラウリル硫酸ナトリウム、四級アンモニウム塩、レシチン、水添レシチンなどが挙げられ、単独または２種以上組み合わせて用いることができる。 Examples of the surfactant component include alkyl allyl polyether alcohol, higher alcohol sulfate, self-emulsifying glyceryl monostearate, sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene polyoxypropylene glycol, propylene glycol fatty acid ester , Polyglycerin fatty acid ester, monoglycerin fatty acid ester, lauromacrogol, sodium lauryl sulfate, quaternary ammonium salt, lecithin, hydrogenated lecithin and the like, and can be used alone or in combination of two or more.
薬物溶解成分としては、例えば、アジピン酸ジイソプロピル、セバシン酸ジエチル、パルミチン酸イソプロピル、ミリスチン酸イソプロピル、中鎖脂肪酸トリグリセリド、ミリスチン酸セチル、ミリスチン酸ミリスチル、ヒマシ油、クロタミトン、スクワラン、スクワレン、炭酸プロピレンなどが挙げられ、単独または２種以上組み合わせて用いることができる。 Examples of the drug-soluble component include diisopropyl adipate, diethyl sebacate, isopropyl palmitate, isopropyl myristate, medium chain triglyceride, cetyl myristate, myristyl myristate, castor oil, crotamiton, squalane, squalene, propylene carbonate, and the like. Can be used alone or in combination of two or more.
精油成分としては、例えば、ｄｌ−メントール、ｌ−メントール、ｌ−メントン、リモネン、ピネン、ピペリトン、テルピネン、テルピノレン、テルピノール、カルベオール、ｄｌ−カンフルなどが挙げられ、単独または２種以上組み合わせて用いることができる。 Examples of the essential oil component include dl-menthol, l-menthol, l-menton, limonene, pinene, piperitone, terpinene, terpinolene, terpinol, carveol, dl-camphor and the like, and these may be used alone or in combination of two or more. Can do.
保湿成分としては、例えば、尿素、グリセリン、ソルビトール、アセチルグルコサミン、ヒアルロン酸などが挙げられ、単独または２種以上組み合わせて用いることができる。 Examples of the moisturizing component include urea, glycerin, sorbitol, acetylglucosamine, hyaluronic acid and the like, and these can be used alone or in combination of two or more.
酸化防止成分としては、例えば、酢酸ｄｌ−α−トコフェロール、ｄｌ−α−トコフェロールおよびｄ−δ−トコフェロールなどのトコフェロール類、ジブチルヒドロキシアニソール、ジブチルヒドロキシトルエン、没食子酸プロピル、Ｌ−アスコルビン酸、アスコルビン酸ナトリウムなどが挙げられ、単独または２種以上組み合わせて用いることができる。 Examples of the antioxidant component include tocopherols such as dl-α-tocopherol acetate, dl-α-tocopherol and d-δ-tocopherol, dibutylhydroxyanisole, dibutylhydroxytoluene, propyl gallate, L-ascorbic acid, ascorbic acid Sodium etc. are mentioned, It can use individually or in combination of 2 or more types.
薬物安定化成分としては、例えば、亜硫酸水素ナトリウム、リン酸水素ナトリウム、エデト酸ナトリウムなどが挙げられ、単独または２種以上組み合わせて用いることができる。 Examples of the drug stabilizing component include sodium bisulfite, sodium hydrogen phosphate, sodium edetate and the like, and these can be used alone or in combination of two or more.
本発明の水性固形軟膏の調製に際しては、従来公知の常法または今後新しく提供される方法で調製することができる。その代表的な調製方法としては、有効成分、ショ糖脂肪酸エステル、脂肪酸塩、低級アルコールの他、多価アルコール成分、ｐＨ調整成分、水、高級アルコール成分、精油成分、界面活性成分、薬物溶解成分、保湿成分、酸化防止成分、薬物安定化成分などを溶解槽に投入し、加熱還流しながら、均一になるまで撹拌する。これを押し出し式やダイヤル繰り出し式などの密閉容器に充填し、室温まで冷却し固化させることにより、調製することができる。 The aqueous solid ointment of the present invention can be prepared by a conventionally known conventional method or a method newly provided in the future. Typical preparation methods include active ingredients, sucrose fatty acid esters, fatty acid salts, lower alcohols, polyhydric alcohol ingredients, pH adjusting ingredients, water, higher alcohol ingredients, essential oil ingredients, surface active ingredients, drug dissolving ingredients. Then, a moisturizing component, an antioxidant component, a drug stabilizing component and the like are put into a dissolution tank, and stirred while being heated to reflux until uniform. It can be prepared by filling this into a closed container such as an extrusion type or a dial feeding type, and cooling to room temperature and solidifying.
以下に、実施例によりさらに詳細に本発明を説明するが、本発明は、これに限定されるものではない。
（実施例１）
表１に示す配合に基づき、後述する調製法１の方法により調製し、本発明の水性固形軟膏１を得た。得られた水性固形軟膏１を後述する試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したときに認められず、また、２５℃で６箇月間保存したときにも認められなかった。結果を表２に示す。
Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited thereto.
Example 1
Based on the formulation shown in Table 1, it was prepared by the method of Preparation Method 1 described later to obtain an aqueous solid ointment 1 of the present invention. When the obtained aqueous solid ointment 1 was evaluated for crystal precipitation according to Test Example 1 described later, crystal precipitation was not observed when stored at 4 ° C. for 3 months, and stored at 25 ° C. for 6 months. It was not recognized even when I did it. The results are shown in Table 2.
（調製法１）
表１に記載の配合比率で原料を量り取り、溶解槽に投入し、沸点まで加温して均一になるまで還流撹拌した。水性固形軟膏を形成すべき各成分の含有量は、その合計が１００重量％となるように、イソプロパノールで適時調整した。その後、これをポリプロピレン製のダイヤル繰り出し式密閉容器に充填し、室温まで冷却して固化させ、ダイヤル繰り出し式密閉容器に充填した本発明の水性固形軟膏を得た。
(Preparation method 1)
The raw materials were weighed at the blending ratio shown in Table 1, put into a dissolution tank, heated to the boiling point, and stirred under reflux until uniform. Content of each component which should form aqueous | water-based solid ointment was timely adjusted with isopropanol so that the sum total might be 100 weight%. Then, this was filled in a polypropylene dial feed-out type airtight container, cooled to room temperature, solidified, and the aqueous solid ointment of the present invention filled in the dial feed-out type airtight container was obtained.
（試験例１）
結晶析出評価
前述の実施例１の水性固形軟膏、後述する実施例２から６の水性固形軟膏および後述する比較例１から９の固形軟膏を、ダイヤル繰り出し式密閉容器に充填した状態のままポリエチレン／アルミラミネート包材にて包装し、４℃で３箇月間または２５℃で６箇月間保存した。次いで、ポリエチレン／アルミラミネート包材および密封容器を開封したのち、固形軟膏部分を繰り出し、結晶析出の有無を確認した。
(Test Example 1)
Evaluation of Crystal Precipitation The aqueous solid ointment of Example 1 described above, the aqueous solid ointment of Examples 2 to 6 to be described later, and the solid ointment of Comparative Examples 1 to 9 to be described later are filled in a dial feed-out type airtight container with polyethylene / It was packed with an aluminum laminate packaging material and stored at 4 ° C. for 3 months or at 25 ° C. for 6 months. Next, after opening the polyethylene / aluminum laminate packaging material and the sealed container, the solid ointment portion was fed out to confirm the presence or absence of crystal precipitation.
（実施例２）
実施例１において、ショ糖脂肪酸エステルを０．０１重量％から０．１０重量％に増やした以外は、実施例１と全く同じ調製法を繰り返し、水性固形軟膏２を得た。得られた水性固形軟膏２を試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したときに認められず、また、２５℃で６箇月間保存したときにも認められなかった。結果を表２に示した。
(Example 2)
In Example 1, except that the sucrose fatty acid ester was increased from 0.01% by weight to 0.10% by weight, exactly the same preparation method as in Example 1 was repeated to obtain an aqueous solid ointment 2. When the obtained aqueous solid ointment 2 was evaluated for crystal precipitation according to Test Example 1, crystal precipitation was not observed when stored at 4 ° C. for 3 months, and when stored at 25 ° C. for 6 months. It was not recognized. The results are shown in Table 2.
（実施例３）
実施例１において、ショ糖脂肪酸エステルを０．０１重量％から０．５０重量％に増やした以外は、実施例１と全く同じ調製法を繰り返し、水性固形軟膏３得た。得られた水性固形軟膏３を試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したときに認められず、また、２５℃で６箇月間保存したときにも認められなかった。結果を表２に示した。
(Example 3)
Except that the sucrose fatty acid ester was increased from 0.01% by weight to 0.50% by weight in Example 1, exactly the same preparation method as in Example 1 was repeated to obtain an aqueous solid ointment 3. When the obtained aqueous solid ointment 3 was evaluated for crystal precipitation according to Test Example 1, no crystal precipitation was observed when stored at 4 ° C. for 3 months, and when stored at 25 ° C. for 6 months. It was not recognized. The results are shown in Table 2.
（実施例４）
実施例１において、ショ糖脂肪酸エステルを０．０１重量％から１．００重量％に増やした以外は、実施例１と全く同じ調製法を繰り返し、水性固形軟膏４得た。得られた水性固形軟膏４を試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したとにき認められず、また、２５℃で６箇月間保存したときにも認められなかった。結果を表２に示した。
Example 4
Except that the sucrose fatty acid ester was increased from 0.01% by weight to 1.00% by weight in Example 1, the same preparation method as in Example 1 was repeated to obtain an aqueous solid ointment 4. When the obtained aqueous solid ointment 4 was evaluated for crystal precipitation according to Test Example 1, the crystal precipitation was not observed when stored at 4 ° C. for 3 months, and was stored at 25 ° C. for 6 months. Sometimes it was not recognized. The results are shown in Table 2.
（実施例５）
実施例１において、ショ糖脂肪酸エステルを０．０１重量％から３．００重量％に増やした以外は、実施例１と全く同じ調製法を繰り返し、水性固形軟膏５を得た。得られた水性固形軟膏５を試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したときに認められず、また、２５℃で６箇月間保存したときにも認められなかった。結果を表２に示した。
(Example 5)
In Example 1, the same preparation method as Example 1 was repeated except that the sucrose fatty acid ester was increased from 0.01% by weight to 3.00% by weight to obtain an aqueous solid ointment 5. When the obtained aqueous solid ointment 5 was evaluated for crystal precipitation according to Test Example 1, no crystal precipitation was observed when stored at 4 ° C. for 3 months, and when stored at 25 ° C. for 6 months. It was not recognized. The results are shown in Table 2.
（実施例６）
実施例４において、ジクロフェナクナトリウムをフルルビプロフェンに変え、ｐＨ調整成分として水酸化ナトリウム０．１６重量％を加えた以外は実施例４と全く同じ調製法を繰り返し、水性固形軟膏６を得た。得られた水性固形軟膏６を前述の試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したときに認められず、また、２５℃で６箇月間保存したときにも認められなかった。結果を表２に示した。
(Example 6)
In Example 4, diclofenac sodium was changed to flurbiprofen, and the same preparation method as in Example 4 was repeated except that 0.16% by weight of sodium hydroxide was added as a pH adjusting component, whereby an aqueous solid ointment 6 was obtained. . When the obtained aqueous solid ointment 6 was evaluated for crystal precipitation according to Test Example 1 described above, crystal precipitation was not observed when stored at 4 ° C. for 3 months, and stored at 25 ° C. for 6 months. It was not recognized even when I did it. The results are shown in Table 2.
（比較例１）
実施例１において、ショ糖脂肪酸エステルを除いた以外は、実施例１と全く同じ調製法を繰り返し、固形軟膏１を得た。得られた固形軟膏１を試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したときに認められ、また、２５℃で６箇月間保存したときにも認められた。結果を表２に示した。
(Comparative Example 1)
In Example 1, except for removing the sucrose fatty acid ester, the same preparation method as in Example 1 was repeated to obtain a solid ointment 1. Crystal precipitation when the obtained solid ointment 1 was evaluated for crystal precipitation according to Test Example 1 was observed when stored at 4 ° C. for 3 months, and also when stored at 25 ° C. for 6 months. Admitted. The results are shown in Table 2.
（比較例２）
実施例４において、ショ糖脂肪酸エステルをクロタミトン（住友化学（株））に変えた以外は、実施例４と全く同じ調製法を繰り返し、固形軟膏２を得た。得られた固形軟膏２を試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したときに認められ、また、２５℃で６箇月間保存したときにも認められた。結果を表２に示した。
(Comparative Example 2)
In Example 4, except that the sucrose fatty acid ester was changed to crotamiton (Sumitomo Chemical Co., Ltd.), exactly the same preparation method as in Example 4 was repeated to obtain a solid ointment 2. Crystal precipitation when the obtained solid ointment 2 was evaluated for crystal precipitation according to Test Example 1 was observed when stored at 4 ° C. for 3 months, and also when stored at 25 ° C. for 6 months. Admitted. The results are shown in Table 2.
（比較例３）
実施例４において、ショ糖脂肪酸エステルをポリオキシエチレン硬化ヒマシ油（ＨＣＯ−４０、日光ケミカルズ（株））に変えた以外は、実施例４と全く同じ調製法を繰り返し、固形軟膏３を得た。得られた固形軟膏３を試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したときに認められ、また、２５℃で６箇月間保存したときにも認められた。結果を表２に示した。
(Comparative Example 3)
In Example 4, except that the sucrose fatty acid ester was changed to polyoxyethylene hydrogenated castor oil (HCO-40, Nikko Chemicals Co., Ltd.), the same preparation method as in Example 4 was repeated to obtain a solid ointment 3. . Crystal precipitation when the obtained solid ointment 3 was evaluated for crystal precipitation according to Test Example 1 was observed when stored at 4 ° C. for 3 months, and also when stored at 25 ° C. for 6 months. Admitted. The results are shown in Table 2.
（比較例４）
実施例４において、ショ糖脂肪酸エステルをステアリン酸アルミニウム（アルミニウムステアレート６００、日油（株））に変えた以外は、実施例４と全く同じ調製法を繰り返し、固形軟膏４を得た。得られた固形軟膏４を試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したときに認められ、また、２５℃で６箇月間保存したときに認められなかった。結果を表２に示した。
(Comparative Example 4)
A solid ointment 4 was obtained in the same manner as in Example 4 except that the sucrose fatty acid ester was changed to aluminum stearate (aluminum stearate 600, NOF Corporation) in Example 4. Crystal precipitation when the obtained solid ointment 4 was evaluated for crystal precipitation according to Test Example 1 was observed when stored at 4 ° C. for 3 months, and also when stored at 25 ° C. for 6 months. I couldn't. The results are shown in Table 2.
（比較例５）
実施例４において、ショ糖脂肪酸エステルをモノカプリル酸プロピレングリコール（ｓｅｆｓｏｌ‐２１８、日光ケミカルズ（株））に変えた以外は、実施例４と全く同じ調製法を繰り返し、固形軟膏５を得た。得られた固形軟膏５を試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したときに認められ、また、２５℃で６箇月間保存したときにも認められた。結果を表２に示した。
(Comparative Example 5)
A solid ointment 5 was obtained in the same manner as in Example 4 except that the sucrose fatty acid ester was changed to propylene glycol monocaprylate (sefsol-218, Nikko Chemicals Co., Ltd.). Crystal precipitation when the obtained solid ointment 5 was evaluated for crystal precipitation according to Test Example 1 was observed when stored at 4 ° C. for 3 months, and also when stored at 25 ° C. for 6 months. Admitted. The results are shown in Table 2.
（比較例６）
実施例４において、ショ糖脂肪酸エステル１．００重量％をκ−カラギーナン（東京化成工業（株））０．８５重量％およびイソステアリン酸（日産化学工業（株））０．１５重量％に変えた以外は、実施例４と全く同じ調製法を繰り返し、固形軟膏６を得た。得られた固形軟膏６は、配合したκ−カラギーナンが溶解せず、外観が著しく悪かった。また、固形軟膏に透明性がないことから結晶析出の評価を行うことができなかった。結果を表２に示す。
(Comparative Example 6)
In Example 4, 1.00% by weight of sucrose fatty acid ester was changed to 0.85% by weight of κ-carrageenan (Tokyo Chemical Industry Co., Ltd.) and 0.15% by weight of isostearic acid (Nissan Chemical Industry Co., Ltd.). Except for the above, the same preparation method as in Example 4 was repeated to obtain a solid ointment 6. The obtained solid ointment 6 did not dissolve the blended κ-carrageenan, and the appearance was remarkably bad. Moreover, since solid ointment is not transparent, the evaluation of crystal precipitation could not be performed. The results are shown in Table 2.
（比較例７）
実施例４において、ショ糖脂肪酸エステルをポリビニルピロリドン（Ｋ−３０Ｗ、（株）日本触媒）に変えた以外は、実施例４と全く同じ調製法を繰り返し、固形軟膏７を得た。得られた固形軟膏７を試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したときに認められ、また、２５℃で６箇月間保存したときにも認められた。結果を表２に示した。
(Comparative Example 7)
In Example 4, except that the sucrose fatty acid ester was changed to polyvinylpyrrolidone (K-30W, Nippon Shokubai Co., Ltd.), the same preparation method as in Example 4 was repeated to obtain a solid ointment 7. Crystal precipitation when the obtained solid ointment 7 was evaluated for crystal precipitation according to Test Example 1 was observed when stored at 4 ° C. for 3 months, and also when stored at 25 ° C. for 6 months. Admitted. The results are shown in Table 2.
（比較例８）
実施例４において、ショ糖脂肪酸エステルをポリオキシエチレンベヘニルエーテル（ＢＢ−２０、日光ケミカルズ（株））に変えた以外は、実施例４と全く同じ調製法を繰り返し、固形軟膏８を得た。得られた固形軟膏８を試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したときに認められ、２５℃で６箇月間保存したときに認められなかった。結果を表２に示した。
(Comparative Example 8)
In Example 4, except that the sucrose fatty acid ester was changed to polyoxyethylene behenyl ether (BB-20, Nikko Chemicals Co., Ltd.), exactly the same preparation method as in Example 4 was repeated to obtain a solid ointment 8. When the obtained solid ointment 8 was evaluated for crystal precipitation according to Test Example 1, crystal precipitation was observed when stored at 4 ° C. for 3 months, but not when stored at 25 ° C. for 6 months. It was. The results are shown in Table 2.
（比較例９）
実施例６において、ショ糖脂肪酸エステルを除いた以外は、実施例６と全く同じ調製法を繰り返し、固形軟膏９を得た。得られた固形軟膏９を試験例１に従って結晶析出評価を行った際の結晶の析出は、４℃で３箇月間保存したときに認められず、２５℃で６箇月間保存したときに認められた。結果を表２に示した。
(Comparative Example 9)
In Example 6, except for removing the sucrose fatty acid ester, the same preparation method as in Example 6 was repeated to obtain a solid ointment 9. Crystal precipitation when the obtained solid ointment 9 was evaluated for crystal precipitation according to Test Example 1 was not observed when stored at 4 ° C. for 3 months, but was observed when stored at 25 ° C. for 6 months. It was. The results are shown in Table 2.
本発明は、脂肪酸塩の結晶析出を抑制することができ、長期間の保存安定性および低温での保存安定性に優れた水性固形軟膏に関するものであって、産業上十分に利用できるものである。
The present invention relates to an aqueous solid ointment that can suppress crystallization of fatty acid salts and is excellent in long-term storage stability and storage stability at low temperatures, and can be sufficiently utilized industrially. .
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016194454A JP6820587B2 (en) | 2016-09-30 | 2016-09-30 | Aqueous solid ointment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016194454A JP6820587B2 (en) | 2016-09-30 | 2016-09-30 | Aqueous solid ointment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018052902A true JP2018052902A (en) | 2018-04-05 |
| JP6820587B2 JP6820587B2 (en) | 2021-01-27 |
Family
ID=61832841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016194454A Active JP6820587B2 (en) | 2016-09-30 | 2016-09-30 | Aqueous solid ointment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6820587B2 (en) |
-
2016
- 2016-09-30 JP JP2016194454A patent/JP6820587B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6820587B2 (en) | 2021-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5668004B2 (en) | Aqueous pharmaceutical composition of 2,6-diisopropylphenol (propofol) and use thereof | |
| JP4526598B2 (en) | Emulsified external preparation and method for producing the same | |
| JPWO2010103845A1 (en) | Topical analgesic / anti-inflammatory agent | |
| WO2010103844A1 (en) | External preparation containing analgesic/anti-inflammatory agent | |
| JP2018021002A (en) | Pharmaceutical preparation containing loxoprofen | |
| WO2018230687A1 (en) | Anti-inflammatory and analgesic drug for external use | |
| WO2006054315B1 (en) | Nonaqueous liquid parenteral aceclofenac formulation | |
| JP2019006736A (en) | Pharmaceutical composition | |
| JP2019006737A (en) | Pharmaceutical composition | |
| JP2023164921A (en) | pharmaceutical composition | |
| JP6820587B2 (en) | Aqueous solid ointment | |
| JP5681883B2 (en) | External preparation composition containing nucleic acid as active ingredient | |
| JP2017137304A (en) | Pharmaceutical preparation containing loxoprofen | |
| JP6956426B2 (en) | Aqueous external preparation | |
| JP2022190025A (en) | External pharmaceutical composition | |
| JP2017155042A (en) | Loxoprofen-containing pharmaceutical formulation | |
| JP6420101B2 (en) | External application agent containing loxoprofen | |
| CN113874011B (en) | External preparation | |
| JP2019006738A (en) | Pharmaceutical composition | |
| JP5827954B2 (en) | Transdermal absorption preparation | |
| JP2011021003A (en) | Aqueous composition | |
| JP2018039775A (en) | Loxoprofen-containing pharmaceutical formulation | |
| CN113164423A (en) | Formulations stabilized with non-aqueous solvents | |
| JP5816881B2 (en) | External preparation composition containing nucleic acid as active ingredient | |
| JP6420102B2 (en) | Loxoprofen-containing external solid preparation and storage stabilizer for the external solid preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190829 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200714 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200911 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20200911 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200911 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201030 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201126 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201223 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6820587 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |